Company Provides Second Quarter 2024 Results of Operations
August 19, 2024 08:00 ET
|
The Singing Machine Company, Inc.
Business Reflects Strategic Shift in Legacy Business Model Fort Lauderdale, FL, Aug. 19, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. (“Singing Machine”) (NASDAQ: MICS) – the...
GREYSTONE LOGISTICS, INC. REPORTS RESULTS OF OPERATIONS FOR THE NINE MONTHS AND THREE MONTHS ENDED FEBRUARY 28, 2023
April 17, 2023 08:00 ET
|
Greystone Logistics Inc.
Tulsa, OK, April 17, 2023 (GLOBE NEWSWIRE) -- (OTCQB:GLGI). Tulsa-based Greystone Logistics, Inc. reports results of operations for the nine and three months ended February 28, 2023. ...
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
May 20, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including...
Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020
March 18, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒‒ FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables...
GREYSTONE LOGISTICS, INC. REPORTS RESULTS OF OPERATIONS FOR THE THREE MONTHS AND SIX MONTHS ENDED NOVEMBER 30, 2020
January 19, 2021 06:00 ET
|
Greystone Logistics Inc.
Tulsa, OK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- GREYSTONE LOGISTICS, INC. (OTCQB:GLGI). Tulsa-based Greystone Logistics, Inc. reports results of operations for the three months and six months ended...
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
November 19, 2020 06:30 ET
|
Entera Bio Ltd.
‒ Completed Enrollment in Phase 2 Clinical Trial of EB613, Positioned as the First Potential Oral Bone Building Product to Treat Osteoporosis ‒‒ Positive Interim 6-Month Bone Mineral Density (BMD)...
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results
August 20, 2020 06:30 ET
|
Entera Bio Ltd.
‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner –‒ Company Expects to Complete Patient Enrollment in...
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
May 21, 2020 06:30 ET
|
Entera Bio Ltd.
‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six...
ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019
March 26, 2020 06:30 ET
|
Entera Bio Ltd.
‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021 ‒‒ Financing Completed in...
ENTERA BIO TO REPORT 2019 BUSINESS AND FINANCIAL RESULTS ON MARCH 26, 2020
March 16, 2020 16:15 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 16, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report...